Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with ...